[CAS NO. 1177827-73-4] AP-III-a4 (ENOblock)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1177827-73-4]
Catalog
SLK-S7443
Brand
Selleck
CAS
1177827-73-4
DESCRIPTION [1177827-73-4]
Overview
| MDL | MFCD28009373 |
|---|---|
| Molecular Weight | 631.18 |
| Molecular Formula | C31H44ClFN8O3 |
| SMILES | O=C(CC1=CC=C(C=C1)NC2=NC(NCC3CCCCC3)=NC(NCC4=CC=C(C=C4)F)=N2)NCCOCCOCCN |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5843 mL | 7.9217 mL | 15.8433 mL |
| 5 mM | 0.3169 mL | 1.5843 mL | 3.1687 mL |
| 10 mM | 0.1584 mL | 0.7922 mL | 1.5843 mL |
| 50 mM | 0.0317 mL | 0.1584 mL | 0.3169 mL |
Description
AP-III-a4 (ENOblock) is the first nonsubstrate analogue inhibitor of with of 0.576 μM.
Targets
| enolase [1] (Cell-free assay) |
| 0.576 μM |
In vitro
In HCT116 cells, AP-III-a4 induces cell death under hypoxia, and inhibits cancer cell migration and invasion by down-regulation of AKT and Bcl-xL expression. In Huh7 hepatocytes and HEK kidney cells, AP-III-a4 induces glucose uptake and inhibits phosphoenolpyruvate carboxykinase (PEPCK) expression.
In vivo
In a HCT116-xenotransplanted zebrafish tumor xenograft model, AP-III-a4 (10 μM) inhibits cancer cell migration and invasion processes. In vivo, AP-III-a4 (10 μM) also causes downregulation of PEPCK expression and induction of glucose uptake, and inhibits adipogenesis and foam cell formation.
Powered by Arctom Copyright © 2026 Arctom.
All rights reserved.